Coronary Microvascular Dysfunction Market is expected to show positive growth, during the forecast period of 2019 to 2032, according to DelveInsight

July 27 19:59 2022
Coronary Microvascular Dysfunction Market is expected to show positive growth, during the forecast period of 2019 to 2032, according to DelveInsight

Coronary Microvascular Dysfunction Market Insights report from DelveInsight provides a thorough understanding of the Coronary Microvascular Dysfunction Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Coronary Microvascular Dysfunction Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.


Coronary Microvascular Dysfunction Overview

Coronary microvascular dysfunction (CMD) is a heart disease that affects the walls and inner lining of tiny coronary artery blood vessels that branch off from the larger coronary arteries. It describes the abnormality in the microcirculation leading to an inadequate vasodilatory response, or a pathological vasoconstrictive response, to physiological or pharmacological stress. Moreover, it carries an increased risk of adverse cardiovascular clinical outcomes.


Download Sample Report-


Regions covered in the report

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Key highlights of the Coronary Microvascular Dysfunction Market Report

  • According to available literature by Nagumo et al. (2022) Coronary Microvascular Dysfunction is more prevalent in females than male.
  • As per Chen et al. (2017), 18%, 10% and 5% of patients with severe, moderate and mild CMD, respectively, had adverse cardiovascular events.
  • The Women’s Ischemia Syndrome Evaluation (WISE) Study found that 74/189 (39%) of women with chest pain but normal coronary arteries had an abnormal CFR consistent with CMD.


Coronary Microvascular Dysfunction Epidemiology Insights

As per Vancheri et al. (2020), CMD is functionally expressed as reduced coronary flow reserve (CFR), which is the maximum increase in coronary blood flow above the resting value after pharmacological coronary vasodilatation. Reduced CFR due to functional and/or structural abnormalities of the microcirculation has been reported in about 50% of patients with chronic coronary syndromes and up to 20% of those with acute coronary syndromes, in the absence of epicardial coronary flow obstruction.


Coronary Microvascular Dysfunction Epidemiology Segmentation in the 7MM

  • Total Coronary Microvascular Dysfunction Prevalent cases
  • Coronary Microvascular Dysfunction Prevalence
  • Coronary Microvascular Dysfunction Gender-specific cases


Do you want to know more information related to report? If yes, visit here-


Coronary Microvascular Dysfunction Treatment Market

Coronary Microvascular Dysfunction treatment starts with lifestyle modification and risk factor control. Management of risk factors includes statins and angiotensin converting enzyme (ACE) inhibitors, in hypertensive patients, which improve endothelial dysfunction represent a first line of treatment in patients with microvascular angina. Furthermore, therapeutically lowering blood pressure can improve CFR, but excess lowering of diastolic blood pressure attenuates the benefit. Insulin sensitizer, metformin, has been shown to improve endothelial function.


Coronary Microvascular Dysfunction Market Insights

Medications like aminophylline and fasudil are under investigation. Aminophylline a nonselective adenosine-receptor antagonist, blocks the mediation of nociception. It is postulated to benefit CMD by attenuating the excess dilation of the microvasculature in a relatively well-perfused area, thus shunting more blood to poorly perfused areas. Fasudil, a rho kinase inhibitor, reduces smooth muscle cell hypercontraction and is being researched currently and has potential for CMD. Furthermore, given that impaired cardiac nociception maybe involved in CMD, tricyclic antidepressants can be considered, as they are thought to have a modulatory effect on norepinephrine uptake and anticholinergic effect that can cause analgesia. Imipramine has been shown to reduce the frequency of pain, but one of the studies did not show any improvement in quality of life, likely because of its significant side effects.


Coronary Microvascular Dysfunction Emerging Therapy Assessment

CMD is highly prevalent and has significant unmet clinical need. More research and large-scale studies are therefore urgently needed to address this important health condition. Currently, pipeline for CMD is limited only comprising of few players; hence, the indication hold enormous opportunities to bring novel innovation to cater to the unmet needs of patients with CMD.


Request Sample Report-


Table of Content

1. Key Insights

2. Coronary Microvascular Dysfunction Executive Summary

3. Coronary Microvascular Dysfunction Competitive Intelligence Analysis

4. Coronary Microvascular Dysfunction: Market Overview at a Glance

5. Coronary Microvascular Dysfunction: Disease Background and Overview

6. Patient Journey

7. Coronary Microvascular Dysfunction Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Coronary Microvascular Dysfunction Unmet Needs

10. Key Endpoints of Coronary Microvascular Dysfunction Treatment

11. Coronary Microvascular Dysfunction Marketed Products

12. Coronary Microvascular Dysfunction Emerging Therapies

13. Coronary Microvascular Dysfunction: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Coronary Microvascular Dysfunction Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Coronary Microvascular Dysfunction Market Drivers

19. Coronary Microvascular Dysfunction Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Coronary Microvascular Dysfunction Market Report Highlights

  • In the coming years, the Coronary Microvascular Dysfunction market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Coronary Microvascular Dysfunction R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for Coronary Microvascular Dysfunction. The launch of emerging therapies will significantly impact the Coronary Microvascular Dysfunction market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Coronary Microvascular Dysfunction
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Coronary Microvascular Dysfunction market
  • To understand the future market competition in the Coronary Microvascular Dysfunction market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Coronary Microvascular Dysfunction in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Coronary Microvascular Dysfunction market
  • To understand the future market competition in the Coronary Microvascular Dysfunction market


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States